Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?
暂无分享,去创建一个
M Rovaris | F Barkhof | M Filippi | C H Polman | F. Barkhof | M. Rovaris | M. Filippi | H. Vrenken | C. Polman | G. Comi | D. Knol | B. Uitdehaag | T. Korteweg | H Vrenken | G Comi | D L Knol | T Korteweg | V Neacsu | B M Uitdehaag | V. Neacsu
[1] Stephen M. Smith,et al. Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.
[2] S. Reingold,et al. Defining the clinical course of multiple sclerosis , 1996, Neurology.
[3] H. Tobi,et al. Correlating MRI and clinical disease activity in multiple sclerosis , 1995, Neurology.
[4] Nick C Fox,et al. Magnetic resonance imaging measures of brain atrophy in multiple sclerosis , 2006, Journal of magnetic resonance imaging : JMRI.
[5] M. Horsfield,et al. A 6‐year clinical and MRI follow‐up study of patients with relapsing–remitting multiple sclerosis treated with Interferon‐beta , 2002, European journal of neurology.
[6] Marco Battaglini,et al. Measuring Brain Atrophy in Multiple Sclerosis , 2007, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[7] M. Rovaris,et al. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial , 2007, Multiple sclerosis.
[8] H. Adams,et al. Progressive cerebral atrophy in MS: A serial study using registered, volumetric MRI , 2000, Neurology.
[9] A. J. Thompson,et al. Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability , 2007, NeuroImage.
[10] Lublin Fd,et al. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. , 1996 .
[11] Frederik Barkhof,et al. Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis. , 2007, Archives of neurology.
[12] Massimo Filippi,et al. Normal-appearing white and grey matter damage in MS , 2007, Journal of Neurology.
[13] F. Barkhof,et al. Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter. , 2006, Radiology.
[14] F. Barkhof,et al. Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue , 2002, Multiple sclerosis.
[15] A J Thompson,et al. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.
[16] J H Simon,et al. Eight-year follow-up study of brain atrophy in patients with MS , 2002, Neurology.
[17] F. Barkhof,et al. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. , 2002, Archives of neurology.
[18] Mark W. Woolrich,et al. Advances in functional and structural MR image analysis and implementation as FSL , 2004, NeuroImage.
[19] Massimo Filippi,et al. European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis , 2001, Annals of neurology.
[20] Nick C Fox,et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis , 2002, Journal of neurology, neurosurgery, and psychiatry.
[21] C. Poser,et al. Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.
[22] Marco Rovaris,et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial , 2004, The Lancet.